Page 263 - 2021_05-Haematologica-web

Letters to the Editor
Pre-published: November 19, 2020.
Disclosures: LV received research support from GenDx and Moderna Therapeutics. None of the other authors has any relevant conflicts of interest to disclose.
Contributions: FC and LV designed the study; VG, RP and EX performed and analyzed the experiments; EB, CT, BM and WM provided advice on chimerism experiments and data interpretation; EX, RG, FG, AAs, MTLS, CC, JP, FC and LV contributed to the clinical care of patients and data collection; AAm supervised the statistical analyses; VG, FC, and LV wrote the manuscript.
Acknowledgments: reagents for this study were generously provided by GenDx. The authors would like to thank UK NEQAS for Leucocyte Immunophenotyping (UK NEQAS LI) for allowing
the use of their samples and data in this study.
Funding: the study was supported by the Italian Ministry of Health (RF-2011-02351998 to FC and LV, RF-2011-02348034 to LV
and TRANSCAN HLALOSS to LV), by the Associazione Italiana per la Ricerca sul Cancro (Start-Up Grant #14162 to LV) and by the DKMS Mechtild Harf Foundation (DKMS Mechtild Harf Research Grant 2015 to LV).
References
1. Horowitz M, Schreiber H, Elder A, et al. Epidemiology and biology of relapse after stem cell transplantation. Bone Marrow Transplant. 2018;53(11):1379-1389.
2.Armand P, Gibson CJ, Cutler C, et al. A disease risk index for patients undergoing allogeneic stem cell transplantation. Blood. 2012;120(4):905-913.
3. Schuurhuis GJ, Heuser M, Freeman S, et al. Minimal/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party. Blood. 2018;131(12):1275-1291.
4. Bader P, Kreyenberg H, Hoelle W, et al. Increasing mixed chimerism defines a high-risk group of childhood acute myelogenous leukemia patients after allogeneic stem cell transplantation where pre-emp- tive immunotherapy may be effective. Bone Marrow Transplant. 2004;33(8):815-821.
5. Alizadeh M, Bernard M, Danic B, et al. Quantitative assessment of hematopoietic chimerism after bone marrow transplantation by real-time quantitative polymerase chain reaction. Blood. 2002; 99(12):4618-4625.
6. Qin X-Y, Li G-X, Qin Y-Z, et al. Quantitative chimerism: an inde- pendent acute leukemia prognosis indicator following allogeneic
hematopoietic SCT. Bone Marrow Transplant. 2014;49(10):1269-
1277.
7.Jacque N, Nguyen S, Golmard J-L, et al. Chimerism analysis in
peripheral blood using indel quantitative real-time PCR is a useful tool to predict post-transplant relapse in acute leukemia. Bone Marrow Transplant. 2015;50(2):259-265.
8. Ahci M, Stempelmann K, Buttkereit U, et al. Clinical utility of quan- titative PCR for chimerism and engraftment monitoring after allo- geneic stem cell transplantation for hematologic malignancies. Biol Blood Marrow Transplant. 2017;23(10):1658-1668.
9. Sellmann L, Rabe K, Bünting I, et al. Diagnostic value of highly-sen- sitive chimerism analysis after allogeneic stem cell transplantation. Bone Marrow Transplant. 2018;53(11):1457-1465.
10. Bader P, Niethammer D, Willasch A, Kreyenberg H, Klingebiel T. How and when should we monitor chimerism after allogeneic stem cell transplantation? Bone Marrow Transplant. 2005;35(2):107-119.
11. Clark JR, Scott SD, Jack AL, et al. Monitoring of chimerism follow- ing allogeneic haematopoietic stem cell transplantation (HSCT): technical recommendations for the use of short tandem repeat (STR) based techniques, on behalf of the United Kingdom National External Quality Assessment Service. Br J Haematol. 2015;168(1):26- 37.
12. Xue E, Tresoldi C, Sala E, et al. Longitudinal qPCR monitoring of nucleophosmin 1 mutations after allogeneic hematopoietic stem cell transplantation to predict AML relapse. Bone Marrow Transplant. 2016;51(3):466-469.
13. Valero-Garcia J, González-Espinosa MDC, Barrios M, et al. Earlier relapse detection after allogeneic haematopoietic stem cell trans- plantation by chimerism assays: digital PCR versus quantitative real- time PCR of insertion/deletion polymorphisms. PLoS One. 2019;14(2):e0212708.
14. Waterhouse M, Pfeifer D, Duque-Afonso J, et al. Droplet digital PCR for the simultaneous analysis of minimal residual disease and hematopoietic chimerism after allogeneic cell transplantation. Clin Chem Lab Med. 2019;57(5):641-647.
15.Stahl T, Böhme MU, Kröger N, Fehse B. Digital PCR to assess hematopoietic chimerism after allogeneic stem cell transplantation. Exp Hematol. 2015;43(6):462-468.
16. Levis MJ, Chen Y-B, Hamadani M, Horowitz MM, Jones RJ. FLT3 inhibitor maintenance after allogeneic transplantation: is a placebo- controlled, randomized trial ethical? J Clin Oncol. 2019;37(19):1604- 1607.
17. De Freitas T, Marktel S, Piemontese S, et al. High rate of hematolog- ical responses to sorafenib in FLT3-ITD acute myeloid leukemia relapsed after allogeneic hematopoietic stem cell transplantation. Eur J Haematol. 2016;96(6):629-636.
haematologica | 2021; 106(5)
1483